Clinical Trial Update: Pyridoxine in Preventing Hand-Foot Syndrome Caused by Capecitabine in Patients With Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating whether pyridoxine can prevent capecitabine-induced hand-foot syndrome in adults with cancer; the study was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• Capecitabine (capecitabine)
• Pyridoxine (Pyridoxine)

Snippet

Sponsor: National Cancer Centre, Singapore | Conditions: Dermatologic Complications, Palmar-plantar Erythrodysesthesia | Phase 3 | Status: TERMINATED